APA (7th ed.) Citation

Salwender, H., Bertsch, U., Benner, A., Raab, M., Hillengaß, J., Hose, D., . . . Goldschmidt, H. (2019). Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: A randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC cancer, 19, . https://doi.org/10.1186/s12885-019-5600-x

Chicago Style (17th ed.) Citation

Salwender, Hans, et al. "Rationale and Design of the German-speaking Myeloma Multicenter Group (GMMG) Trial HD6: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction/consolidation and Lenalidomide Maintenance in Patients with Newly Diagnosed Myeloma." BMC Cancer 19 (2019). https://doi.org/10.1186/s12885-019-5600-x.

MLA (9th ed.) Citation

Salwender, Hans, et al. "Rationale and Design of the German-speaking Myeloma Multicenter Group (GMMG) Trial HD6: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction/consolidation and Lenalidomide Maintenance in Patients with Newly Diagnosed Myeloma." BMC Cancer, vol. 19, 2019, https://doi.org/10.1186/s12885-019-5600-x.